Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen McCarthy

Showing results (41-50 of 69) with videos related to

Pageof 7
Sort By:
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 30, 2017
Transdermal delivery of gentamicin using dissolving microneedle arrays for potential treatment of neonatal sepsisPatricia González-Vázquez, Eneko Larrañeta, Maelíosa T C McCrudden, et al.
British Journal of Haematology|December 30, 2016
Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidationAbraham M Varghese, Dena R Howard, Christopher Pocock, et al.
Blood|February 15, 2003
High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemiaHelen McCarthy, William G Wierda, Lynn L Barron, et al.
British Journal of Haematology|March 21, 2022
Guideline for the treatment of chronic lymphocytic leukaemiaRenata Walewska, Nilima Parry-Jones, Toby A Eyre, et al.
British Journal of Haematology|August 28, 2014
Bone marrow assessment in asymptomatic IgM monoclonal gammopathies - reply to Varettoni et alRoger G Owen, Guy Pratt, Rebecca L Auer, et al.
British Journal of Haematology|February 18, 2014
Guidelines on the diagnosis and management of Waldenström macroglobulinaemiaRoger G Owen, Guy Pratt, Rebecca L Auer, et al.
British Journal of Haematology|August 20, 2024
PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's MacroglobulinaemiaJaimal Kothari, Toby Eyre, Ali Rismani, et al.
Blood|July 30, 2025
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLLJan A Burger, Paul M Barr, Tadeusz Robak, et al.
British Journal of Haematology|July 17, 2018
Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology GuidelineAnna H Schuh, Nilima Parry-Jones, Niamh Appleby, et al.
Blood Advances|September 9, 2025
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN studyRamón García-Sanz, Roger G Owen, Wojciech Jurczak, et al.
Pageof 7

Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Journal of Controlled Release : Official Journal of the Controlled Release Society|July 30, 2017
Transdermal delivery of gentamicin using dissolving microneedle arrays for potential treatment of neonatal sepsisPatricia González-Vázquez, Eneko Larrañeta, Maelíosa T C McCrudden, et al.
British Journal of Haematology|December 30, 2016
Eradication of minimal residual disease improves overall and progression-free survival in patients with chronic lymphocytic leukaemia, evidence from NCRN CLL207: a phase II trial assessing alemtuzumab consolidationAbraham M Varghese, Dena R Howard, Christopher Pocock, et al.
Blood|February 15, 2003
High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemiaHelen McCarthy, William G Wierda, Lynn L Barron, et al.
British Journal of Haematology|March 21, 2022
Guideline for the treatment of chronic lymphocytic leukaemiaRenata Walewska, Nilima Parry-Jones, Toby A Eyre, et al.
British Journal of Haematology|August 28, 2014
Bone marrow assessment in asymptomatic IgM monoclonal gammopathies - reply to Varettoni et alRoger G Owen, Guy Pratt, Rebecca L Auer, et al.
British Journal of Haematology|February 18, 2014
Guidelines on the diagnosis and management of Waldenström macroglobulinaemiaRoger G Owen, Guy Pratt, Rebecca L Auer, et al.
British Journal of Haematology|August 20, 2024
PembroWM: A phase II trial to investigate the safety and efficacy of rituximab and pembrolizumab in relapsed/refractory Waldenström's MacroglobulinaemiaJaimal Kothari, Toby Eyre, Ali Rismani, et al.
Blood|July 30, 2025
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLLJan A Burger, Paul M Barr, Tadeusz Robak, et al.
British Journal of Haematology|July 17, 2018
Guideline for the treatment of chronic lymphocytic leukaemia: A British Society for Haematology GuidelineAnna H Schuh, Nilima Parry-Jones, Niamh Appleby, et al.
Blood Advances|September 9, 2025
Outcomes after transition from ibrutinib to zanubrutinib in patients with Waldenström macroglobulinemia from the ASPEN studyRamón García-Sanz, Roger G Owen, Wojciech Jurczak, et al.
Pageof 7